
    
      1. participants

           a. eligible participants are randomly assigned to dabigatran, rivaroxaban, or apixaban
           with allocation ratio of 1:1:1

             -  Patients are randomly assigned to receive dabigatran (110 or 150 mg twice daily),
                rivaroxaban (15 or 20 mg daily), or apixaban (5 mg twice daily) with dosage and
                frequency approved by the Ministry of Health and Welfare, Taiwan. Reduced doses
                (dabigatran 110 mg twice daily, rivaroxaban 10 or 15 mg daily, or apixaban 2.5 mg
                twice daily) are allowed in a subset of patients with one or more of the following
                criteria: an age of at least 80 years, a body weight of no more than 60 kg, a serum
                creatinine level ≥1.5 mg per deciliter (133 μmol per liter) or creatinine clearance
                around 30 to 49 ml per minute)

        2. blood sampling, genotyping, and measurement of biomarkers

           a. bood samples (13 mL) from peripheral veins in all study subjects at baseline and 10
           mL 3 months later, and stored for enzyme-linked immunosorbent assay as well as
           genotyping

        3. outcome follow-up a. clinical follow-up is performed and clinical outcomes are obtained
           by clinic visit, telephone call or direct contact with participants or subjects' family
           quarterly after treatment for 2 times, then every 6 months
    
  